CSS
BOLT icon

Cubist Systematic Strategies’s Bolt Biotherapeutics BOLT Stock Holding History

Cubist Systematic Strategies’s Portfolio BOLT Stock Details BOLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-511
Closed -$15K – 4258
2022
Q3 		$15K Sell
511
-220
-30% -$9.1K ﹤0.01% 4259
2022
Q2 		$30K Buy
+731
New +$28.4K ﹤0.01% 4170
2022
Q1 		– Sell
-945
Closed -$93K – 3565
2021
Q4 		$93K Buy
945
+585
+163% +$111K ﹤0.01% 3213
2021
Q3 		$91K Buy
+360
New +$102K ﹤0.01% 2757

Other funds holding BOLT

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return

Cubist Systematic Strategies's BOLT Position: Q4 2022 in Review

Cubist Systematic Strategies sold out of Bolt Biotherapeutics (BOLT) in Q4 2022, closing a stake of 511 shares — an estimated $15K sold.

Cubist Systematic Strategies first reported a position in BOLT in Q3 2021 and held it in 4 quarters. The position peaked at $93K in Q4 2021. 44 funds tracked by Wall St. Rank hold BOLT as of Q4 2022.

  • Cubist Systematic Strategies reported no remaining Bolt Biotherapeutics position as of Q4 2022 after selling out during the quarter.
  • Cubist Systematic Strategies sold 511 Bolt Biotherapeutics shares in Q4 2022, an estimated $15K.
  • Cubist Systematic Strategies first reported a position in Bolt Biotherapeutics in Q3 2021 and held it in 4 quarters.
  • Cubist Systematic Strategies's Bolt Biotherapeutics position peaked at $93K in Q4 2021.
  • 44 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q4 2022.

Based on Cubist Systematic Strategies's 13F filing for Q4 2022, filed 14 Feb 2023.